Fujiwara, Keiichi <br/><br/>
Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1.  [electronic resource] 

 -  Liver international : official journal of the International Association for the Study of the Liver  Jun 2006 
 - 520-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1478-3223 
<br/><br/><label>Standard No.: </label>10.1111/j.1478-3231.2006.01263.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Dose-Response Relationship, Drug<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C--drug therapy<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Japan<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>RNA, Viral--blood<br/>Recombinant Proteins<br/>Ribavirin--administration & dosage<br/>Treatment Outcome